1 Rare variant effect estimation and polygenic risk prediction

2

3 Kisung Nam¹, Minjung Kho¹, Wei Zhou^{2,3,4}, Bhramar Mukherjee⁵, Seunggeun Lee¹

- 4
- 5 Abstract
- 6

7 Due to their low frequency, estimating the effect of rare variants is challenging. Here, we 8 propose RareEffect, a method that first estimates gene or region-based heritability and then 9 each variant effect size using an empirical Bayesian approach. Our method uses a variance 10 component model, popular in rare variant tests, and is designed to provide two levels of effect 11 sizes, gene/region-level and variant-level, which can provide better interpretation. To adjust for the case-control imbalance in phenotypes, our approach uses a fast implementation of the 12 13 Firth bias correction. We demonstrate the accuracy and computational efficiency of our 14 method through extensive simulations and the analysis of UK Biobank whole exome 15 sequencing data for five continuous traits and five binary disease phenotypes. Additionally, we show that the effect sizes obtained from our model can be leveraged to improve the 16 17 performance of polygenic scores.

¹ Graduate School of Data Science, Seoul National University, Seoul, South Korea

² Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA

³ Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA

⁴Nornerams in Mindicaphand Rongulation Genetics beroad Institute of Milliand Harvard, Cambridge in Millis Apractice.

⁵ Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA

19 Introduction

With the availability of extensive sequencing data in biobanks¹, the study of rare variants has 20 21 become more feasible than ever before. Rare variants have been identified as potential causative factors for numerous complex diseases²⁻⁸, and their exploration is crucial in 22 unraveling the genetic risk factors of complex traits⁹. To identify the association between rare 23 variants and complex traits, gene or region-based tests^{10,11}, including the Burden test, the 24 sequence kernel association test (SKAT)¹² and its adaptive optimized version (SKAT-O)¹³, have 25 been commonly used. Recently, several methods, including STAAR¹⁴, SAIGE-GENE¹⁵, and 26 SAIGE-GENE+¹⁶ are developed to run region-based tests in biobank scale data. 27

28

To elucidate the effect of rare variants on complex diseases and traits and utilize them for risk prediction, in addition to calculating p-values for association tests, effect size estimation is required. However, estimating the effect size of rare variants remains a challenge. The low minor allele frequencies make single variant-based estimations unstable. Popular association tests like SKAT and SKAT-O are score tests, so only provide p-values. Although the Burden test approach provides a gene-burden effect size, this may not accurately reflect the true effect of rare variants in the presence of null variants and variants with opposing association directions.

37 To address the challenges, we introduce RareEffect, a novel method that estimates gene or region-based heritability and subsequently calculates each variant's effect size using an 38 39 empirical Bayesian approach. Utilizing a variance component model, similar to that in the SKAT test, our method offers dual-level effect size estimation, region-level and variant-level, for 40 enhanced interpretability. Unlike the Burden approach, our model flexibly estimates effect 41 42 sizes in a data-driven manner. To reduce the computational burden for estimating variance 43 components, we implemented the Factored Spectrally Transformed Linear Mixed Models (FaST-LMM)¹⁷, which leverages the low rank of the genetic relatedness matrix. We also utilize 44 45 the strategy to collapse ultra-rare variants, as used in SAIGE-GENE+, to reduce the sparsity of the genotype matrix and improve power of estimating the effect of ultra-rare variants. For 46 47 binary traits, we additionally apply a fast implementation of the Firth bias reduction method to stably estimate the effect sizes. 48

50 From simulation studies, we showed that the proposed method is computationally fast and 51 reliably estimates each gene heritability. We also showed that the proposed approach 52 outperformed linear regression or ridge regression in terms of root mean squared error (RMSE) 53 for estimating the individual-variant level effect sizes. From the UK Biobank (UKB) Whole 54 Exome Sequencing (WES) data analysis of 5 quantitative traits and 5 binary disease traits, we 55 demonstrate that exonic rare variants can explain substantial phenotypic variabilities, but the 56 degree differs by phenotypes. We also showed that our approach has higher explanatory 57 power in explaining the phenotype variability compared to models based on burden tests. 58 These findings provide strong evidence for the practical utility of our method in leveraging 59 rare variant data for risk prediction and heritability estimation.

60

61 Result

62 *Overview of methods*

Our proposed method encompasses three steps. The overview of the method is outlined in
Fig. 1 and is described in detail in the Methods section.

65

In step 1, we fit a null linear or logistic mixed-effect model without genotypes to estimate the covariate effects. This step involves fitting the model using the average information restricted maximum likelihood (AI-REML)¹⁸ approach, which is utilized in the SAIGE¹⁹ and GMMAT²⁰ framework. Residuals will be used as covariate-adjusted phenotypes in the subsequent steps.

71 In step 2, we model the effect of rare variants (MAF \leq 0.01) as random effects and estimate the 72 variance components, and hence heritability. To mitigate the computational demands, we adopt the Factored Spectrally Transformed Linear Mixed Models (FaST-LMM)¹⁷. Given $n \gg k$, 73 FaST-LMM reduces the computation cost from $O(n^3)$ of conventional mixed model algorithm 74 to $O(nk^2)$ where n is the number of samples in the dataset and k is the number of genetic 75 76 variants in a single group (See Methods). Additionally, we leveraged the sparsity in genotypes. 77 To incorporate the fact that genetic effects vary by functional annotations, we fit the model 78 separately for distinct categories, and then combine them to calculate gene or region-level 79 heritability. For whole exome analysis, we include three functional categories: (1) Loss-of-80 function (LoF) variants; (2) missense variants; and (3) synonymous variants. Within each

category, the ultra-rare variants, defined as those with a minor allele count (MAC) of lower
than 10, are collapsed into a single variant, as employed in SAIGE-GENE+¹⁶. As estimating
multiple variance components due to distinct functional groups is not feasible with FaST-LMM,
we marginally calculate variance component for each functional group separately, and then
adjust them using method of moments (MoM) approach (See **Methods**).

86

87 In step 3, following the estimation of variance components, we calculate the effect size of each variant using the Best Linear Unbiased Predictor (BLUP) estimates²¹⁻²⁴. We further estimate 88 89 the prediction error variance (PEV) of the effect size estimates to assess the reliability of the 90 variant-level effect sizes. Additionally, using the estimated PEV, we can obtain confidence 91 intervals for each variant-level effect size. For binary traits, we implemented Firth bias 92 correction as a subsequent step. This correction mechanism mitigates bias and rectifies 93 abnormal estimates, especially in scenarios where the case-control ratio is imbalanced. 94 Recognizing the imperative of scalability in large-scale biobank data analyses, we developed a 95 fast implementation of Firth correction, which reduces computation complexity from $O(Mnk_F)$ to $O(n_{nz}k_F)$ where M is the average number of iterations for convergence of Firth 96 97 corrected beta, n_{nz} is the number of individuals with non-zero genotype, and k_F denotes the 98 number of variants that needs to be corrected (See Methods).

99

100 UK Biobank WES data analysis

101 We applied our method to five quantitative traits (HDL cholesterol, LDL cholesterol, 102 triglycerides, height, body mass index (BMI)) and five binary traits (breast cancer, prostate 103 cancer, lymphoid leukemia, type 2 diabetes, and coronary atherosclerosis) in UKB. For LDL 104 cholesterol (LDL-C) level, we adjusted the pre-medication levels by dividing the raw LDL-C level 105 by 0.7 for individuals on cholesterol-lowering medication²⁵.

106

We computed gene-level effect sizes by leveraging the estimated heritability derived from the mixed effects model. Recognizing the inherent unsigned nature of heritability, we assign a sign by incorporating variant-level effect sizes of loss-of-function (LoF) variants within each gene. This allows us to discern the direction of the effect of the gene on the trait (See **Methods**). As expected, the gene-based association test p-values and the magnitude of the gene-level effect size showed a substantial correlation (**Fig. 2** and **Supplementary Figure 1**). Incorporating gene-

medRxiv preprint doi: https://doi.org/10.1101/2024.06.23.24309366; this version posted June 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

113 level effect size and direction on top of the gene-based association tests can add significant 114 value to genetic analyses. For example, the signed heritability clearly shows that the 115 impairment of APOC3 function increases HDL cholesterol (HDL-C) level but decreases 116 triglycerides (**Fig. 2(a)** and **2(c)**).

117

118 We estimated the variant-level effect sizes of exonic variants and presented two genes, APOC3 119 and SLC12A3, on HDL-C levels as examples (Fig. 3). As expected, variants demonstrating 120 significant associations, in terms of p-values, also exhibited larger effect sizes. Using RareEffect, 121 we observed that the majority of variants in APOC3 displayed positive effect sizes. The Burden 122 and SKAT-O p-values from SAIGE-GENE+ were both highly significant (Burden p-value = 1×10^{-298} and SKAT-O p-value = 1×10^{-300}). In contrast, variants in *SLC12A3* exhibited both 123 124 positive and negative effect sizes. Consequently, Burden p-value was not significant (Burden p-value = 0.01), but the SKAT-O p-value was significant (Burden p-value = 7×10^{-12}). This 125 126 distinction in the directionality of effect sizes cannot be discerned through the burden approach. 127

128

129 We extended our analyses to estimate polygenic risk scores using rare variants with effect 130 sizes estimated from RareEffect (PRS_{RF}). The UK Biobank data were randomly split into training and test sets (ratio = 8:2), and PRS_{RE} was constructed using the genes with p-values 131 $< 2.5 \times 10^{-6}$ from SAIGE-GENE+ in the training set (See **Methods**). We included top 10 genes 132 when the number of genes with p-values $< 2.5 \times 10^{-6}$ is smaller than 10. We further 133 integrated these PRS_{RE} with PRS derived from common variants (PRS_{common}) to evaluate the 134 135 practical utility of our approach. When combining the PRS from common and rare variants, we constructed a composite score, a linear combination of PRS from common and rare 136 variants. We evaluated the predictive performance in terms of R^2 . Our methods consistently 137 138 exhibited superior prediction accuracy for all tested quantitative traits, compared to a comparative approach that relied on per-allele effect sizes derived from burden tests (Fig. 4, 139 140 Supplementary Table 1, and Supplementary Figure 2).

141

The improvement became particularly pronounced when predicting lipid phenotypes among individuals deemed at high risk. For instance, when predicting HDL and LDL cholesterol levels, PRS_{RE} achieved R^2 of 0.4737 and 0.6287 when restricting individuals with top/bottom 0.5%

in terms of PRS_{RE} . When the composite score was used for risk prediction, R^2 were 0.6237 145 146 and 0.6645 when restricted top/bottom 0.5% individuals. In contrast, common variants only PRS model had lower R^2 (0.5417 for HDL and 0.5823 for LDL) for top/bottom 0.5% individuals. 147 Notably, the sub-groups identified as high-risk by PRS_{common} and PRS_{RE} were substantially 148 distinct (Supplementary Figure 3), underscoring the complementary nature of rare variants in 149 detecting individuals at elevated disease risk. Additionally, we observed that our model 150 showed higher predictability compared to the Burden approach which showed R^2 of 0.3683 151 and 0.2262 for HDL and LDL with top/bottom 0.5% in terms of PRS using burden score 152 153 (*PRS*_{burden}), respectively.

154

155 Our method exhibited marginally lower predictive performance for binary traits, as measured 156 by AUC, compared to the burden approach. We observed that for chosen binary traits, there 157 were fewer genes associated with the trait, and their signals appeared weaker when 158 contrasted with tested continuous traits. Nonetheless, our method offers potential benefits, 159 as it can enhance predictability by combining PRS_{RE} with PRS_{common} and PRS_{burden} , which yielded better results. For instance, in the case of lymphoid leukemia, when evaluating 160 161 individuals in the top/bottom 0.5% based on common PRS, the $PRS_{common} + PRS_{RE} +$ PRS_{burden} approach exhibited an AUC of 0.8649, whereas the $PRS_{common} + PRS_{burden}$ 162 approach demonstrated an AUC of 0.8559, with the common-only approach yielding an AUC 163 of 0.8559. 164

165

We further examined the relationship between phenotype outliers and the PRS in identifying 166 individuals at high risk for common diseases²⁶. We first defined the phenotype outliers as 167 individuals with phenotype value exceeding a certain z-score cutoff and calculated the 168 169 proportion of individuals with high PRS among phenotype outliers. Specifically, for LDL cholesterol levels, PRS_{RE} successfully pinpointed individuals at phenotypic extremes, who 170 exhibited a tenfold higher likelihood of possessing a PRS_{RE} falling within 0.1st percentile 171 compared to the baseline population (Supplementary Figure 4). PRS_{RE} and PRS_{common} 172 173 utilize distinct set of variants and show minimal correlation (Supplementary Table 2). Therefore, integrating these models into a unified framework enables the identification of a 174 175 significantly larger cohort at high risk than achievable through *PRS*_{common} alone.

177 Simulation study

To assess the predictive accuracy of our method, we conducted extensive simulations under diverse scenarios (see **Methods**) for both binary and quantitative traits. To mimic real data, we utilized actual genotypes from the UKB dataset, specifically the array-genotyped data for common variants (MAF \geq 0.01) and the UKB WES data for rare variants (MAF \leq 0.01).

182

183 We compared the performance of our method against other existing approaches such as 184 linear regression, which is used for standard single-variant association test, or ridge regression 185 in terms of RMSE. For quantitative traits, our method consistently demonstrated a lower RMSE 186 of 0.1703 on average, outperforming the comparative methods which showed RMSE of 0.1770 187 (ridge regression) to 0.1881 (linear regression) (Supplementary Table 3) when estimating the 188 effect size. For binary traits, our method also exhibited lower predictive error particularly in 189 scenarios of low disease prevalence compared to ridge regression (Supplementary Table 4). 190 Conversely, ridge regression showed marginally reduced error compared to our method in 191 instances of high disease prevalence; however, the difference in accuracy remains modest.

192

193 Computation and memory cost

194 Analyzing 166,960 samples from the UKB WES data to estimate the effect size of the DOCK6 gene, which contains 4,114 rare variants, we observed that the computation time for 195 196 RareEffect with a simulated phenotype was approximately 90% lower than that of ridge 197 regression. Specifically, RareEffect completed the analysis in 4.2 seconds, compared to 44.6 198 seconds for ridge regression (Supplementary Figure 5). The memory usage for RareEffect 199 during the analysis was 1.14GB for DOCK6 gene (Supplementary Figure 6). For binary traits, 200 an additional step of performing Firth bias correction is required. We observed that the 201 normal Firth bias correction process took 708 seconds to analyze a gene with 250 variants 202 (after collapsing) across 342,409 individuals. However, by implementing our fast version of Firth correction, the computation time was dramatically reduced to 2.9 seconds 203 204 (Supplementary Figure 7).

205

206 Discussion

207 Our study introduces a novel method aimed at estimating the effect size of rare variants and 208 can be extended to estimate gene-level effect size by employing a two-stage framework of 209 generalized linear mixed models. By leveraging the variant-level effect size estimates obtained 210 through our approach, we can examine the collective impact of rare variants within a gene 211 and quantify their contribution to the overall heritability of complex traits.

212

213 In order to obtain accurate estimates for effect sizes while optimizing computational efficiency, 214 we employed several techniques in our analysis. First, we utilized the FaST-LMM¹⁷ algorithm 215 to expedite computation and reduce memory usage. FaST-LMM leverages the spectral 216 decomposition of the genetic relatedness matrix, allowing for efficient calculation of the 217 variance component in mixed models. Second, we implemented the optimized version of Firth 218 bias correction by utilizing the sparsity of genotype matrix and skipping the computation of 219 hat matrix at every iteration. Third, we employed a collapsing strategy that reduces the 220 sparsity of the data, similar to the approach employed in SAIGE-GENE+. These algorithmic 221 approaches significantly accelerate the estimation process and enhance computational 222 scalability, particularly when dealing with large-scale datasets and complex genetic analyses 223 involving rare variants.

224

225 Beyond its immediate applications in effect size estimation, our proposed method offers 226 significant potential for enhancing polygenic risk prediction models. Traditionally, these 227 models have relied on common variants, often neglecting the valuable insights provided by rare variants. Our analysis reveals that the correlation between PRS_{RF} and phenotype values 228 229 in the general population is not substantial (Supplementary Figure 8). However, we 230 demonstrate that the RareEffect method effectively identifies individuals with high genetic 231 risk. By incorporating our approach, we can substantially improve the predictive accuracy and precision of polygenic risk scores. 232

233

Al-based methods^{27,28} have been developed to enhance the pathogenicity prediction of rare variants. Although these approaches help to identify effect sizes of pathogenic variants and can be used for risk prediction, they may not be as effective for identifying beneficial or gainof-function variants. Additionally, the performance of these methods can be limited when applied to non-protein-altering variants. Our approach can accommodate the predictively

pathogenic variants identified by AI-based models by forming them into a separate category,thereby enhancing performance.

241

242 Our study, however, is not without limitations. While RareEffect demonstrates comparable or 243 superior performance in estimating the effect size for simulated binary phenotypes, our 244 evaluation revealed only marginal enhancements in predictive performance, as measured by 245 the area under the curve (AUC), compared to the traditional common PRS across tested disease phenotypes. This could be attributed to the trait's reliance on a limited number of 246 247 ultra-rare variants, which our method collapses into super-variants, thereby complicating the 248 estimation of variant-level effect sizes for true causal variants. Despite its efficacy in effect size 249 estimation, RareEffect's ability to improve prediction accuracy remains constrained, 250 highlighting a potential area for future refinement and investigation for risk prediction of 251 binary traits. Additionally, it is important to note that RareEffect is based on BLUP estimate, 252 characterized by shrinkage properties, leading to biased estimates of effect sizes. However, 253 despite this bias, RareEffect provides more stable estimates compared to unbiased methods 254 like linear regression, which tend to be unstable for rare variant analysis due to the low allele 255 frequency inherent in such variants.

256

In summary, our results demonstrate that incorporating information from rare variants enables the accurate estimation of gene-level and variant-level effect sizes, as well as the identification of high-risk individuals who might remain undetected by conventional polygenic risk scores (PRS) methods relying on common variants.

- 261
- 262

263 Method

264 Generalized linear mixed model

We denote the phenotype of the *i*th individual using y_i for both quantitative and binary traits in a study with sample size *n*. *X* represents the $n \times (p + 1)$ vector with *p* covariates including the intercept and G_j is the $n \times k$ matrix representing the minor allele counts for *k* rare variants in gene or region *j*. The generalized linear mixed model (GLMM) can be expressed as: $g(\mu) = X\alpha + G_i\beta_i + b$

where $\boldsymbol{\mu}$ is the mean phenotype, $\boldsymbol{b} \sim MVN(0, \sigma_q^2 \boldsymbol{K})$ is the random effect, and \boldsymbol{K} is an $n \times n$ 270 genetic relatedness matrix (GRM). And g is the link function which is an identity function for 271 quantitative traits with error term $\epsilon \sim MVN(0, \sigma_e^2 I_n)$ and a logit function for binary traits. The 272 273 parameter α is a $(p + 1) \times 1$ vector of fixed effect coefficients and β_i is a $k \times 1$ vector of the 274 random genetic effect. 275 276 Fitting the null generalized mixed model (step 1) 277 We used the average information restricted maximum likelihood (AI-REML) algorithm to fit the null GLMM (i.e., H_0 : $\boldsymbol{\beta}_i = \mathbf{0}$) as in SAIGE step 1. 278 279 Estimation of the gene-level (region-level) heritability (step 2) 280 281 We estimate the effect size of rare variants using the following linear mixed model: 282 $\widetilde{\mathbf{y}} = \mathbf{G}_i \mathbf{\beta}_i + \boldsymbol{\epsilon}$ where $\tilde{y} = (\tilde{y}_1, ..., \tilde{y}_n)^T = y - \hat{y}$ for quantitative traits, $\tilde{y}_i = \frac{d\eta_i}{d\mu_i}(y_i - \hat{\mu}_i) = \frac{1}{\hat{\mu}_i(1-\hat{\mu}_i)}(y_i - \hat{\mu}_i)$ 283 284 $\hat{\mu}_i$), a working residual from iteratively reweighted least squares (IRWLS) for binary traits, and 285 $\hat{\mu}_i$ is the mean phenotype for individual *i*, which can be obtained from step 1. When obtaining 286 G_i , as in SAIGE-GENE+, we collapsed ultra-rare variants with minor allele count (MAC) \leq 10 by 287 each gene and functional group to reduce the sparsity. We further implemented an option to 288 collapse all loss-of-function (LoF) rare variants into a single column, irrespective of their minor 289 allele count, adopting the burden approach. This approach is predicated on the assumption 290 that all rare LoF variants share a common effect size and direction. For binary traits, when we 291 use working residuals, the variance of \tilde{y}_i differs by individual, so we cannot apply the optimization technique of FaST-LMM. Therefore, we divide both sides by the square root of 292 293 variance of \tilde{y}_i to make the variance be the same across individuals. We estimate the effect 294 size using the modified model, for binary traits:

$$\widehat{\boldsymbol{\Sigma}}_{\epsilon}^{-\frac{1}{2}}\widetilde{\boldsymbol{y}} = \widehat{\boldsymbol{\Sigma}}_{\epsilon}^{-\frac{1}{2}}\boldsymbol{G}_{j}\boldsymbol{\beta}_{j} + \widehat{\boldsymbol{\Sigma}}_{\epsilon}^{-\frac{1}{2}}\boldsymbol{\epsilon}$$

296 where $\widehat{\Sigma}_{\epsilon} = \text{diag}(\frac{1}{\widehat{\mu}_{l}(1-\widehat{\mu}_{l})}).$

297

In this model, the prior distribution of $\boldsymbol{\beta}_{j}$ are assumed to follow $MVN(0, \tau \boldsymbol{\Sigma})$, and the noise $\boldsymbol{\epsilon}$ is assumed to follow $MVN(0, \psi \boldsymbol{I}_{n})$ for quantitative traits, while we assume $\hat{\boldsymbol{\Sigma}}_{\boldsymbol{\epsilon}}^{-\frac{1}{2}} \boldsymbol{\epsilon}$ follows

300 $MVN(0, \psi I_n)$ for binary traits. When there is no prior knowledge of the correlation within β , 301 Σ is set to be an identity matrix. But in general, Σ does not have to be an identity or a diagonal 302 matrix.

303

To estimate the variance component parameters (τ, ψ) , we use factored spectrally transformed linear mixed models (FaST-LMM) algorithm. Let $\tilde{G} = [\tilde{G}_1, ..., \tilde{G}_k]$ be an $n \times k$ genotype matrix of the region with $\tilde{G}_j = G_j$ for quantitative traits and $\tilde{G}_j = \hat{\Sigma}_{\epsilon}^{-\frac{1}{2}}G_j$ for binary traits. The variance of \tilde{y} (quantitative traits) or $\hat{\Sigma}_{\epsilon}^{-\frac{1}{2}}\tilde{y}$ (binary traits) can be written as $\tau \tilde{G}\Sigma \tilde{G}^T + \psi I_n$

309

Traditional approaches to estimate the variance components require either calculating inverse 310 matrix or conducting spectral decomposition of the $n \times n$ matrix $\widetilde{\mathbf{G}} \Sigma \widetilde{\mathbf{G}}^T$, so the time 311 complexity is of $O(n^3)$. In contrast, FaST-LMM algorithm uses the fact that $\tilde{\mathbf{G}} \Sigma \tilde{\mathbf{G}}^T$ has rank at 312 most k, so to reduce the computation complexity. Suppose $\mathbf{Z} = \widetilde{\mathbf{G}}\mathbf{L}$ is an $n \times k$ matrix where 313 L is a Cholesky factor of Σ . Then $\widetilde{G}\Sigma\widetilde{G}^T = ZZ^T$. FaST-LMM carries out singular value 314 decomposition on **Z** and calculate likelihood for (τ, ψ) . With given $n \gg k$, calculation of 315 Z and its singular value decomposition requires only $O(nk^2)$ of time complexity. And we 316 further improved the computation efficiency utilizing the sparsity of Z^{29} . In biobank-scale data, 317 318 *n* is in the hundreds of thousands, and *k* is in the tens to hundreds on average which means 319 $n \gg k$.

320

Using the above optimization technique, we estimate the variance components by each group.

322 Consider one group (LoF, missense or synonymous) in a single gene *j* in the model:

323

$$\widetilde{\mathbf{y}} = \mathbf{G}_{\cdot,i}\mathbf{\beta}_{\cdot,i} + \mathbf{\epsilon}$$

We first marginally estimate the maximum-likelihood estimator (MLE) of variance components $\tau_{LoF,j}$, $\tau_{mis,j}$, and $\tau_{syn,j}$. As the marginal estimates do not account for LD among variants in different groups, we adjust the estimates using method of moments (MoM) approaches³⁰. The MoM estimator can be obtained by solving the following linear system:

328 $\begin{bmatrix} \mathbf{T} & \mathbf{b} \\ \mathbf{b}^T & n \end{bmatrix} \begin{bmatrix} \hat{\mathbf{\tau}} \\ \hat{\psi} \end{bmatrix} = \begin{bmatrix} \mathbf{c} \\ \tilde{\mathbf{y}}^T \tilde{\mathbf{y}} \end{bmatrix}$

where **T** is a 3 × 3 matrix for joint estimation or a scalar (1 × 1 matrix) for marginal estimation with entries $\mathbf{T}_{k,l} = \operatorname{tr}(\widetilde{\mathbf{G}}_k \boldsymbol{\Sigma}_k \widetilde{\mathbf{G}}_k^T \widetilde{\mathbf{G}}_l \boldsymbol{\Sigma}_l \widetilde{\mathbf{G}}_l^T)$ where $k, l \in \{1, 2, 3\}$ for joint estimation. **b** is a 3-vector for joint estimation or a scalar for marginal estimation with entries $b_k = \sum_{k=1}^{\infty} \sum_{k=1$

332 $\operatorname{tr}(\widetilde{\boldsymbol{G}}_k\boldsymbol{\Sigma}_k\widetilde{\boldsymbol{G}}_k^T), \boldsymbol{c}$ is a 3-vector for joint estimation or a scalar for marginal estimation with entries

333
$$c_k = \widetilde{\boldsymbol{y}}^T \widetilde{\boldsymbol{G}}_k \boldsymbol{\Sigma}_k \widetilde{\boldsymbol{G}}_k^T \widetilde{\boldsymbol{y}}$$
, and $\widehat{\boldsymbol{\tau}} = \begin{bmatrix} \tau_1 \\ \widehat{\tau}_2 \\ \widehat{\tau}_3 \end{bmatrix}$ where (τ_1, τ_2, τ_3) denotes $(\tau_{LoF,j}, \tau_{mis,j}, \tau_{syn,j})$ for a single

334 gene *j*, respectively.

335

After estimating the marginal and joint MoM estimator of variance components, we adjustthe MLE of the marginal variance components by:

338
$$\hat{\tau}_{i,j} = \hat{\tau}_{MLE,mar,i,j} \times \frac{\hat{\tau}_{MOM,joint,i,j}}{\hat{\tau}_{MOM,mar,i,j}}$$

where $i \in \{LoF, mis, syn\}$. The MoM estimator of the variance component was not directly utilized in our study since the MoM estimator could yield negative variance components. In cases of the variance component estimated by the MoM is negative, we used marginal variance component without adjustment. Both MoM and likelihood-based approaches exhibited the similar trends of variance components (**Supplementary Figure 9**). Additionally, we assume that the variance explained by rare variants in a single gene is negligibly small compared to the total variance of \tilde{y} , therefore, $\hat{\psi} \approx Var(\tilde{y})$.

346

We estimated the heritability from rare variants of gene *j* using these adjusted variance components. In a joint model,

349
$$Var(\widetilde{\mathbf{y}}) = \mathbf{G}_j \mathbf{\Sigma}_j \mathbf{G}_j^T + \psi \mathbf{I}_n$$

350 where
$$\boldsymbol{G}_{j} = [\boldsymbol{G}_{LOF,j} \ \boldsymbol{G}_{mis,j} \ \boldsymbol{G}_{syn,j}]$$
 and $\boldsymbol{\Sigma}_{j} = \begin{bmatrix} \hat{\tau}_{LOF,j} \boldsymbol{\Sigma}_{LOF,j} & \boldsymbol{0} & \boldsymbol{0} \\ \boldsymbol{0} & \hat{\tau}_{mis,j} \boldsymbol{\Sigma}_{mis,j} & \boldsymbol{0} \\ \boldsymbol{0} & \boldsymbol{0} & \hat{\tau}_{syn,j} \boldsymbol{\Sigma}_{syn,j} \end{bmatrix}$.

351 Therefore,

352
$$\sum_{i=1}^{n} Var(\tilde{y}_{i}) = tr(\boldsymbol{G}_{j}\boldsymbol{\Sigma}_{j}\boldsymbol{G}_{j}^{T}) + n\psi \quad \text{(for quantitative traits)}$$

353
$$\sum_{i=1}^{n} Var(\tilde{y}_{i}) = tr(\boldsymbol{G}_{j}\boldsymbol{\Sigma}_{j}\boldsymbol{G}_{j}^{T}) + n tr(\widehat{\boldsymbol{\Sigma}}_{\epsilon}) \quad \text{(for binary traits)}$$

354

355 Subsequently, the heritability from rare variants of gene j can be denoted as:

356
$$h_j^2 = \frac{\operatorname{tr}(\boldsymbol{G}_j \boldsymbol{\Sigma}_j \boldsymbol{G}_j^T)}{\operatorname{tr}(\boldsymbol{G}_j \boldsymbol{\Sigma}_j \boldsymbol{G}_j^T) + n \psi} \quad \text{(for quantitative traits)}$$

$$h_j^2 = rac{ ext{tr}ig(m{G}_j m{\Sigma}_j m{G}_j^T ig)}{ ext{tr}ig(m{G}_j m{\Sigma}_j m{G}_j^T ig) + \psi ext{tr}ig(m{\widehat{\Sigma}}_{m{\epsilon}} ig)}$$
 (for binary traits)

Additionally, to determine the direction of the gene-level effect, we obtained the sign of the linear combination of the effect sizes of loss-of-function variants in a gene, weighted by their MAFs:

361 (signed heritability of gene j) = $h_j^2 \times \text{sgn}(\sum_{j \in LoF} \beta_j MAF_j)$

362 This measure gives the information of the magnitude of genetic effects from rare variants in a363 single gene and its direction of effects.

364

357

365 Estimation of the variant-level effect size (step 3)

366 The effect sizes at variant-level resolution are estimated using the adjusted variance 367 components in the previous step by:

368

$$\widehat{\boldsymbol{\beta}}_{j} = \left(\widetilde{\boldsymbol{G}}_{j}^{T}\widetilde{\boldsymbol{G}}_{j} + \widehat{\boldsymbol{\psi}}\boldsymbol{\Sigma}_{j}^{-1}\right)^{-1}\widetilde{\boldsymbol{G}}_{j}^{T}\widetilde{\boldsymbol{y}}$$

369 for each gene or region.

370

371 We further estimated the prediction error variance (PEV) by:

372
$$PEV(\widehat{\boldsymbol{\beta}}_{j}) = \left(\widetilde{\boldsymbol{G}}_{j}^{T}\widetilde{\boldsymbol{G}}_{j} + \frac{\widehat{\boldsymbol{\psi}}}{\widehat{\boldsymbol{t}}}\boldsymbol{I}\right)^{-1}$$

373 for each gene or region. Using this PEV, we can obtain confidence intervals for effect sizes.

374

For binary traits, the Firth bias correction³¹ is a more accurate method to estimate SNP effect sizes³²⁻³⁴, particularly in cases marked by a significant case-control imbalance. We incorporate this correction into our analytical framework. Additionally, we introduce an L2 penalty term to account for the prior distribution of β . The Firth corrected effect estimates can be calculated numerically by optimizing the following objective function:

380
$$\hat{\beta}_* = \operatorname{argmax}_{\beta} [\log L(\beta) + \frac{1}{2} \log |I(\beta)| - \frac{1}{2\hat{\tau}} ||\beta||_2^2]$$

381 where L denotes the likelihood function and I is the Fisher information.

383 To improve computational efficiency, we developed the fast implementation of Firth bias correction. First, we compute the hat matrix, $H = W^{\frac{1}{2}} X (X^T W X)^{-1} X^T W^{\frac{1}{2}}$, $W = \text{diag}(\hat{\mu}) (1 - 1)^{\frac{1}{2}} X (1 - 1)^$ 384 $(\hat{\mu}_{i})$), only once rather than recalculating it at each iteration, assuming that the iterative 385 386 weights (W) change slowly as a function of the mean $\mu_i^{20,35}$. We compared, using both 387 simulation and real data, the difference in effect size estimates between computing the hat 388 matrix once and computing it at each iteration. Our findings indicate minimal differences in 389 the effect size estimates (Supplementary Figure 10). Given that Firth correction is applied to each variant, we iterate the hat matrix calculation for k_F times, where k_F represents the 390 number of variants that need to be corrected. This strategy results in a reduction in the 391 392 computational complexity with Firth correction from $O(Mnk_F)$ to $O(nk_F)$, where M is the average number of iterations needed for Firth corrected effect size convergence. Second, we 393 394 extend Firth correction to accommodate sparse genotype matrices. Specifically, we restrict 395 our computations to individuals with non-zero genotypes when determining the score and 396 Fisher information. This further reduces the time complexity of the Firth correction, now at 397 $O(n_{nz}k_F)$, where n_{nz} denotes the number of individuals with non-zero genotype. Considering that we are estimating the effect size of rare variants with MAF < 0.01, we 398 observed that $n_{nz} < 0.01n$ which implies that leveraging sparsity makes the estimation of 399 400 effect sizes more than 100 times faster compared to a non-sparse approach.

401

We note that Firth correction is used when the absolute value of estimated effect size ($\hat{\beta}$) surpasses a predefined threshold. In this study, we used threshold of log 2 \approx 0.693 for simulation studies and real data analysis.

405

406 Rare-variant PRS calculation

407 We further calculated polygenic risk scores using the variant-level effect sizes of rare variants 408 (PRS_{RE}) in genes with gene-level p-value from SAIGE-GENE+ lower than 2.5×10^{-6} . PRS_{RE} 409 of individual *i* can be calculated as:

410
$$PRS_{RE,i} = \sum_{j \in J} \boldsymbol{G}_{ij} \widehat{\boldsymbol{\beta}}_j$$

411 where *J* denotes a set of genes with gene-level p-value lower than 2.5×10^{-6} . Additionally, 412 we combined these PRS_{RE} with PRS_{common} only. We applied PRS-CS³⁶ to obtain the variant-

level weights for the calculation the *PRS_{common}*. We compared the predictive performance 413 of the *PRS_{RE}* to *PRS_{burden}*. *PRS_{burden}* were obtained in two different ways: (1) collapsing all 414 415 rare variants into one super-variant regardless of the functionality of the variants and (2) 416 collapsing rare variants by functionality of the variants (LoF, missense, and synonymous). After collapsing, we fitted the following linear model to estimate the per-allele effect sizes: 417 418 $\tilde{y} = \boldsymbol{G}_{burden,j} \boldsymbol{\beta}_{burden,j}$ The burden PRS are also calculated as a linear combination of per-allele effect sizes and the 419 420 collapsed genotypes of each individual. 421 We compared the predictive performance in terms of R^2 for quantitative traits, and the area 422 423 under receiver operating characteristic curve (AUROC) for binary traits of the following linear models: 424 425 $\tilde{y} \sim PRS_{composite}$ $\tilde{y} \sim PRS_{common} + PRS_{RE}$ 426 $\tilde{y} \sim PRS_{common} + PRS_{burden}$ 427 where $PRS_{composite}$ is a linear combination of PRS_{common} and PRS_{RE} with weights trained 428 429 from the training set. 430 UK Biobank data analysis 431 In this study, we used WES data of 393,247 White British participants in the UK Biobank. The 432 UK Biobank is a UK-based prospective cohort of ~500,000 individuals aged 40 to 69 at 433 enrollment. We split the train and test data 8:2 randomly for the PRS evaluation. We applied 434 435 quality control (QC) procedures prior to the analysis. We first removed redundant samples and individuals with sex mismatch or sex chromosome aneuploidy. Additionally, we further 436 437 removed variants with a missingness rate across individuals > 0.1, HWE p-value < 10^{-15} , and 438 monomorphic variants. We generated group files, which define the list of variants in genes and its functional annotation, by using the loss-of-function transcript effect estimator 439 (LOFTEE)³⁷. We regarded a variant as loss-of-function (LoF) only in case of it is labeled as a 440 high-confidence (HC) LoF variant, and variants with low-confidence (LC) were regarded as 441 442 missense variants. 443

medRxiv preprint doi: https://doi.org/10.1101/2024.06.23.24309366; this version posted June 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Using the data after QC, we applied our method to five quantitative traits (HDL cholesterol,
LDL cholesterol, triglycerides, height, and body mass index) and five binary traits (breast
cancer, prostate cancer, lymphoid leukemia, type 2 diabetes, and coronary atherosclerosis).
We defined the disease by mapping ICD-10 codes to Phecodes using the PheWAS R package³⁸.

448

449 Simulation study

To generate outcome phenotypes, we used the following model for quantitative and binarytraits:

452

$$y_{i} = X_{i1} + X_{i2} + G_{i,common}\beta_{common} + G_{i,rare}\beta_{rare} + \epsilon$$

453 $logit(P(Y_i = 1)) = \alpha + X_{i1} + X_{i2} + G_{i,common}\beta_{common} + G_{i,rare}\beta_{rare}$

454 where X_{i1} and X_{i2} are covariates, and $G_{i,common}$ and $G_{i,rare}$ are genotype vectors of common 455 variants and rare variants of *i*th individual, respectively. The intercept α for binary traits is determined by the disease prevalence. The covariates X_{i1} and X_{i2} were simulated from 456 457 Bernoulli(0.5) and N(0, 1), respectively. For common variant effect, we randomly selected 458 L = 30,000 LD-pruned common variants with MAF > 1%, and assumed that the effect size of single common variant follows $N(0, \frac{1}{r})$. We selected 10 causal genes in UKB WES 200k data for 459 460 generation of phenotypes. We used eight different scenarios regarding rare variants: (1) 461 proportion of causal variants, (2) effect size of causal variants, and (3) direction of effect within a single gene. For the proportion of causal variants, we assumed (1) 20% of LoF, 10% of 462 463 missense, and 2% of synonymous variants, or (2) 30% of LoF, 10% of missense, and 2% of synonymous variants among rare variants that are not ultra-rare are causal. For ultra-rare 464 465 variants, we assumed that the proportion of causal variants are three times higher than the 466 non-ultra-rare variants, that is, (1) 60% of LoF, 30% of missense, and 6% of synonymous ultra-467 rare variants, or (2) 90% of LoF, 30% of missense, and 6% of synonymous ultra-rare variants 468 are causal. Regarding the effect size of causal variants, we assumed that the absolute effect sizes of causal variants are (1) $|0.5 \log_{10} MAF|$ for LoF variants, and $|0.25 \log_{10} MAF|$ for 469 missense and synonymous variants, or (2) $|0.3 \log_{10} MAF|$ for LoF variants, and 470 471 $|0.15\log_{10} MAF|$ for missense and synonymous variants. We further assumed that the effect 472 directions are (1) the same among all causal variants in a single gene, or (2) same for 100% of 473 LoF, 80% of missense, and 50% of synonymous variants, while remaining variants have the

474 opposite direction of effect. For eight combinations of scenarios, we repeated the simulation

475 for 100 times.

476

477 Computation cost evaluation

We evaluated the computation time and memory usage using simulated data as described above, comprising 166,960 individuals of White British ancestry from the UKB WES 200k dataset. Additionally, we examined computation time and memory usage across subsets with sample sizes of 10k, 30k, 50k, and 100k. For each generative scenario, we reported the mean of 5 attempts for computation times and memory usage, comparing them with multiple linear regression, simple linear regression (as in GWAS), and ridge regression. The evaluation for linear regression and ridge regression was done using Im and gIm functions in R, respectively.

486 Data availability

- The analysis results for 5 quantitative and 5 binary phenotypes of UKB WES data analysis
 results are available at: <u>https://storage.googleapis.com/leelabsg/RareEffect/RareEffect</u>
 <u>effect size.zip</u> (variant-level effect size) and <u>https://storage.googleapis.com/leelabsg/</u>
 <u>RareEffect/RareEffect h2.zip</u> (gene-level signed heritability).
- 491

492 Code availability

- RareEffect is implemented as a part of SAIGE software, which is an open-source R package,
 available at https://github.com/saigegit/SAIGE. RareEffect is available in SAIGE version 1.3.7
 or higher.
- 496

497 Author Contribution

- K.N. and S.L. designed experiments. K.N. performed experiments and analyzed the UKB WES
 data. K.N. and S.L. implemented the software with input from W.Z. M.K. and B.M. provided
 helpful advice. K.N. and S.L. wrote the manuscript with input from all co-authors.
- 501

502 Acknowledgements

- This research was supported by the Brain Pool Plus (BP+) Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (2020H1D3A2A03100666) and the grants funded by the Ministry of Food and Drug Safety, Republic of Korea (Grant Number: 23212MFDS202). This research was conducted using the UK Biobank Resource under application number 45227.
- 508
- 509

510 References

- Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.
 Nature 562, 203-209 (2018).
- 513 2. Gibson, G. Rare and common variants: twenty arguments. *Nat Rev Genet* 13, 135-45
 514 (2012).
- Kryukov, G.V., Shpunt, A., Stamatoyannopoulos, J.A. & Sunyaev, S.R. Power of deep, all exon resequencing for discovery of human trait genes. *Proc Natl Acad Sci U S A* **106**,
 3871-6 (2009).
- 5184.MacArthur, D.G. et al. A systematic survey of loss-of-function variants in human519protein-coding genes. Science 335, 823-8 (2012).

- 520 5. Genomes Project, C. *et al.* An integrated map of genetic variation from 1,092 human 521 genomes. *Nature* **491**, 56-65 (2012).
- 522 6. Rivas, M.A. *et al.* Deep resequencing of GWAS loci identifies independent rare variants
 523 associated with inflammatory bowel disease. *Nat Genet* 43, 1066-73 (2011).
- 524 7. Saint Pierre, A. & Génin, E. How important are rare variants in common disease? 525 *Briefings in Functional Genomics* **13**, 353-361 (2014).
- 526 8. Perrone, F., Cacace, R., van der Zee, J. & Van Broeckhoven, C. Emerging genetic
 527 complexity and rare genetic variants in neurodegenerative brain diseases. *Genome*528 *Med* 13, 59 (2021).
- 529 9. Manolio, T.A. *et al.* Finding the missing heritability of complex diseases. *Nature* 461, 530 747-53 (2009).
- 53110.Lee, S., Abecasis, G.R., Boehnke, M. & Lin, X. Rare-variant association analysis: study532designs and statistical tests. Am J Hum Genet **95**, 5-23 (2014).
- 533 11. Chen, W., Coombes, B.J. & Larson, N.B. Recent advances and challenges of rare variant
 534 association analysis in the biobank sequencing era. *Front Genet* 13, 1014947 (2022).
- 535 12. Wu, M.C. *et al.* Rare-variant association testing for sequencing data with the sequence
 536 kernel association test. *Am J Hum Genet* **89**, 82-93 (2011).
- Lee, S. *et al.* Optimal unified approach for rare-variant association testing with
 application to small-sample case-control whole-exome sequencing studies. *Am J Hum Genet* 91, 224-37 (2012).
- Li, X. *et al.* Dynamic incorporation of multiple in silico functional annotations
 empowers rare variant association analysis of large whole-genome sequencing studies
 at scale. *Nat Genet* 52, 969-983 (2020).
- 54315.Zhou, W. *et al.* Scalable generalized linear mixed model for region-based association544tests in large biobanks and cohorts. *Nat Genet* **52**, 634-639 (2020).
- 54516.Zhou, W. *et al.* SAIGE-GENE+ improves the efficiency and accuracy of set-based rare546variant association tests. *Nat Genet* **54**, 1466-1469 (2022).
- 547 17. Lippert, C. *et al.* FaST linear mixed models for genome-wide association studies. *Nat*548 *Methods* 8, 833-5 (2011).
- 549 18. Gilmour, A.R., Thompson, R. & Cullis, B.R. Average information REML: An efficient
 550 algorithm for variance parameter estimation in linear mixed models. *Biometrics* 51,
 551 1440-1450 (1995).
- 55219.Zhou, W. et al. Efficiently controlling for case-control imbalance and sample553relatedness in large-scale genetic association studies. Nat Genet 50, 1335-1341 (2018).
- 554 20. Chen, H. *et al.* Control for Population Structure and Relatedness for Binary Traits in
 555 Genetic Association Studies via Logistic Mixed Models. *Am J Hum Genet* **98**, 653-66
 556 (2016).
- 55721.Robinson, G.K. That BLUP is a Good Thing: The Estimation of Random Effects. Statistical558Science 6, 15-32, 18 (1991).
- 559 22. Henderson, C.R. Best Linear Unbiased Estimation and Prediction under a Selection
 560 Model. *Biometrics* **31**, 423-447 (1975).
- 56123.Maier, R.M. *et al.* Improving genetic prediction by leveraging genetic correlations562among human diseases and traits. *Nat Commun* **9**, 989 (2018).
- 563 24. Chen, C.Y., Han, J., Hunter, D.J., Kraft, P. & Price, A.L. Explicit Modeling of Ancestry
 564 Improves Polygenic Risk Scores and BLUP Prediction. *Genet Epidemiol* **39**, 427-38
 565 (2015).

- 566 25. Graham, S.E. *et al.* The power of genetic diversity in genome-wide association studies 567 of lipids. *Nature* **600**, 675-679 (2021).
- 568 26. Fiziev, P.P. *et al.* Rare penetrant mutations confer severe risk of common diseases.
 569 *Science* 380, eabo1131 (2023).
- 570 27. Sundaram, L. *et al.* Predicting the clinical impact of human mutation with deep neural 571 networks. *Nat Genet* **50**, 1161-1170 (2018).
- 572 28. Gao, H. *et al.* The landscape of tolerated genetic variation in humans and primates.
 573 *Science* 380, eabn8153 (2023).
- 57429.Berry, M.W. Large-Scale Sparse Singular Value Computations. International Journal of575Supercomputer Applications and High Performance Computing 6, 13-49 (1992).
- 576 30. Pazokitoroudi, A. *et al.* Efficient variance components analysis across millions of genomes. *Nat Commun* **11**, 4020 (2020).
- 578 31. Firth, D. Bias Reduction of Maximum Likelihood Estimates. *Biometrika* **80**, 27-38 (1993).
- 579 32. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for 580 quantitative and binary traits. *Nat Genet* **53**, 1097-1103 (2021).
- 58133.Wang, X. Firth logistic regression for rare variant association tests. Front Genet 5, 187582(2014).
- 58334.Dey, R., Schmidt, E.M., Abecasis, G.R. & Lee, S. A Fast and Accurate Algorithm to Test584for Binary Phenotypes and Its Application to PheWAS. Am J Hum Genet 101, 37-49585(2017).
- 58635.Breslow, N.E. & Clayton, D.G. Approximate Inference in Generalized Linear Mixed587Models. Journal of the American Statistical Association 88, 9-25 (1993).
- 58836.Ge, T., Chen, C.Y., Ni, Y., Feng, Y.A. & Smoller, J.W. Polygenic prediction via Bayesian589regression and continuous shrinkage priors. Nat Commun 10, 1776 (2019).
- 59037.Karczewski, K.J. *et al.* The mutational constraint spectrum quantified from variation in591141,456 humans. *Nature* **581**, 434-443 (2020).
- 59238.Wu, P. et al.Mapping ICD-10 and ICD-10-CM Codes to Phecodes: Workflow593Development and Initial Evaluation. JMIR Med Inform 7, e14325 (2019).
- 594 595

- 596 Figures Legends
- 597 Fig. 1. Overview of RareEffect.
- 598 Fig. 2. Estimated signed heritability for lipid phenotypes using 392,748 White British
- 599 samples in UK Biobank whole exome sequencing data
- 600 Fig. 3. Variant-level effect size on HDL cholesterol for variants in APOC3 gene (chromosome
- 601 **11) and SLC12A3 gene (chromosome 16)**
- 602 Fig. 4. Comparison of performance of risk prediction models for lipid phenotypes using
- 603 **314,198** White British samples (80% of the whole White British samples) in UK Biobank
- 604 whole exome sequencing data

605 Fig. 1. Overview of RareEffect.

606



607 RareEffect encompasses three steps. In step 1, we fit a null GLMM using AI-REML approach, 608 and obtain residuals for the subsequent steps. In step 2, we divide variants by gene and its 609 functional annotation (LoF, missense, and synonymous). We first estimate the variance

610 component of each group and adjust them using MoM approach. In step 3, we calculate the 611 variant-level effect size using BLUP estimates. For binary traits, Firth bias correction is 612 additionally applied to adjust the case-control imbalance. Through RareEffect, we provide 613 region-level and variant-level effect sizes for enhanced interpretability and improved risk 614 prediction performance.

616 Fig. 2. Estimated signed heritability for lipid phenotypes using 392,748 White British

617 samples in UK Biobank whole exome sequencing data



- 619 Signed gene-level heritability from RareEffect for (a) HDL cholesterol level, (b) LDL
- 620 cholesterol level, and (c) triglycerides level. Gene-level p-values were obtained from SAIGE-
- 621 GENE+, and we included genes with p-values < 2.5×10^{-6} . The *x*-axis represents the rank
- order of genes based on their gene-level p-values. Lower ranks correspond to genes with
- 623 more significant p-values. The *y*-axis shows the signed gene-level heritability for each gene.
- 624 Signed heritability indicates the direction (positive or negative) and magnitude of the genetic
- 625 contribution of the gene to the trait.





627 11) and SLC12A3 gene (chromosome 16).

Variant-level effect size on HDL cholesterol level for (a) APOC3 and (b) SLC12A3 genes. Gene-633 634 level p-values were obtained from SAIGE-GENE+, and we included genes with p-values < 2.5×10^{-6} . The left panel shows the effect size of collapsed ultra-rare variants categorized by 635 636 their functional annotations: loss-of-function (LoF), missense, and synonymous, respectively. 637 The right panel displays the variant-level effect size of rare variants. Variants are color-coded based on their functional annotation: red for LoF, blue for missense, and green for 638 synonymous. The shapes of the points indicate the significance of the variants: circles 639 represent p-values > 0.05, diamonds represent p-values between 5×10^{-8} and 0.05, and 640 triangles represent p-values $< 5 \times 10^{-8}$. Single-variant p-values were obtained from SAIGE, 641 while the p-values of collapsed variants were derived from linear regression by regressing \tilde{y} 642 643 on each collapsed variant. The exon region is shaded.

I

Top/Bottom

Top/Bottom

644 Fig. 4. Comparison of performance of risk prediction models for lipid phenotypes using 645 314,198 White British samples (80% of the whole White British samples) in UK Biobank 646 whole exome sequencing data.

- 647
- 648



All

0.0



I

Top/Bottom

Top/Bottom



Method

Burden (B)

RareEffect (R)

Common (C) Composite (C + R)C + R + B



Coefficient of determination (R^2) of the risk prediction models for (a) HDL cholesterol level, (b) LDL cholesterol level, and (c) Triglycerides level. We evaluated the R^2 of five models using: (1) PRS_{burden} only, (2) PRS_{RE} only, (3) PRS_{common} only, (4) composite score, (5) $PRS_{common} + PRS_{RE} + PRS_{burden}$ by five subgroups: (1) all samples, (2) samples with top/bottom 10% PRS, (3) samples with top/bottom 5% PRS, (4) samples with top/bottom 1% PRS, and (5) samples with top/bottom 0.5% PRS. The black vertical lines represent the 95% confidence interval of the R^2 estimates.

663 Supplementary Figures		
664	1.	Estimated signed heritability for 10 tested traits
665	2.	Predictive performance for 10 tested traits
666	3.	Relationship between common PRS (PRS_{common}) and RareEffect PRS (PRS_{RE})
667	4.	Enrichment of high-risk individuals in terms of RareEffect PRS (PRS_{RE}), common
668		variant PRS (<i>PRS_{common}</i>) and composite score in phenotype outliers
669	5.	Computation time of RareEffect, linear regression, and ridge regression
670	6.	Memory Usage of RareEffect by number of variants
671	7.	Computation time of the fast implementation Firth bias correction and the normal
672		Firth correction
673	8.	Relationship between RareEffect PRS (PRS_{RE}) and phenotype values
674	9.	Comparison of estimated variance components between RareEffect and MoM
675		estimator
676	10	Comparison of estimated effect size between computing the hat matrix at every
677		iteration and only once in Firth bias correction
678		
679 Supplementary Tables		
680	1.	Predictive performance for 10 tested phenotypes in UK Biobank
681	2.	Pearson correlation between PRS_{common} and PRS_{RE}
682	3.	Predictive performance (RMSE) for simulated continuous data by scenario

683 4. Predictive performance (RMSE) for simulated binary data by scenario